CGON CG ONCOLOGY INC revenue, earnings and financials
For the quarter ended June 30, 2026, CG ONCOLOGY INC reported revenue of $1.16M, net income of −$79.1M and diluted EPS of −$0.90; over the last four quarters revenue was $6.23M and net income −$224M; for the fiscal year ended December 2025 revenue was $4.04M, up 254.7% on the year before.
CGON annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $4.04M, gross profit n/a, operating income −$191M, net income −$161M (margin -3985.1%), EPS −$2.08
- Fiscal year ended Dec 2024: revenue $1.14M, gross profit n/a, operating income −$115M, net income −$88.0M (margin -7729.6%), EPS −$1.41
- Fiscal year ended Dec 2023: revenue $204K, gross profit n/a, operating income −$55.4M, net income −$48.6M (margin -23827.0%), EPS −$15.65
CGON quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $1.16M, net income −$79.1M, EPS −$0.90
- Quarter ended Mar 31, 2026: revenue $1.08M (up 1982.7% year over year), net income −$60.2M, EPS −$0.71
- Quarter ended Dec 31, 2025 (from the annual report): revenue $2.32M (up 409.2% year over year), net income −$41.3M, EPS −$0.52
- Quarter ended Sep 30, 2025: revenue $1.67M (up 3774.4% year over year), net income −$43.8M, EPS −$0.57
- Quarter ended Jun 30, 2025: revenue $0 (down 100.0% year over year), net income −$41.4M, EPS −$0.54
- Quarter ended Mar 31, 2025: revenue $52.0K (down 90.2% year over year), net income −$34.5M, EPS −$0.45
- Quarter ended Dec 31, 2024 (from the annual report): revenue $456K (up 45500.0% year over year), net income −$31.8M, EPS −$0.47
- Quarter ended Sep 30, 2024: revenue $43.0K (up 377.8% year over year), net income −$20.4M, EPS −$0.30
- Quarter ended Jun 30, 2024: revenue $111K, net income −$18.9M, EPS −$0.28
- Quarter ended Mar 31, 2024: revenue $529K (up 172.7% year over year), net income −$16.9M, EPS −$0.36
- Quarter ended Dec 31, 2023 (from the annual report): revenue $1.00K, net income −$16.6M, EPS −$4.50
- Quarter ended Sep 30, 2023: revenue $9.00K, net income −$11.8M, EPS −$4.00
- Quarter ended Jun 30, 2023: revenue $0, net income −$11.6M, EPS −$3.93
- Quarter ended Mar 31, 2023: revenue $194K, net income −$8.67M, EPS −$3.22
CGON cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$132M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$78.7M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$45.7M, share buybacks n/a
CGON balance sheet
- Jun 30, 2026: cash $19.6M, total assets $1.09B, total liabilities $56.5M, shareholders' equity $1.03B, long-term debt $3.00M
- Mar 31, 2026: cash $33.7M, total assets $1.14B, total liabilities $43.5M, shareholders' equity $1.09B, long-term debt $3.00M
- Dec 31, 2025: cash $32.5M, total assets $792M, total liabilities $39.0M, shareholders' equity $753M, long-term debt $3.00M
- Sep 30, 2025: cash $45.1M, total assets $730M, total liabilities $42.3M, shareholders' equity $688M, long-term debt $3.00M
- Jun 30, 2025: cash $14.6M, total assets $701M, total liabilities $31.1M, shareholders' equity $670M
- Mar 31, 2025: cash $41.5M, total assets $728M, total liabilities $23.4M, shareholders' equity $705M
- Dec 31, 2024: cash $257M, total assets $755M, total liabilities $21.4M, shareholders' equity $733M, long-term debt $0
- Sep 30, 2024: cash $43.4M, total assets $552M, total liabilities $15.7M, shareholders' equity $537M
What is CGON's revenue?
CG ONCOLOGY INC reported $6.23M of revenue over its last four quarters, through June 30, 2026.
Is CGON profitable?
No. CG ONCOLOGY INC lost $224M over the last four quarters.
What is CGON's EPS?
Diluted earnings per share over the last four quarters were −$2.70; −$0.90 in the latest quarter.